Mehmet Sitki Copur, MD, on Inadequacies of the Clinical Trials System Highlighted by COVID-19
The expert oncologist/hematologist spoke with CancerNetwork® about the challenges brought to light by the current pandemic.
The expert oncologist/hematologist spoke with CancerNetwork® about the challenges brought to light by the current pandemic.
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
Biennial screening mammography is recommended for those who are 40 to 74 years old rather than individualizing screening decisions in this age group.
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Biennial screening mammography is recommended for those who are 40 to 74 years old rather than individualizing screening decisions in this age group.
Findings from the CheckMate-901 trial support the CHMP’s positive opinion of nivolumab plus chemotherapy in metastatic urothelial carcinoma.
Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.
Those who have been previously treated for KRAS G12C–mutated advanced NSCLC may benefit from treatment with glecirasib.
Findings from the phase 3 DESTINY-Breast06 trial will be presented at a future medical meeting and shared with regulatory authorities.